Lodenosine

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H328052

CAS#: 110143-10-7

Description: Lodenosine, also known as DDG-1; FddA; Fddl; NSC-613792, is a RNA-directed DNA polymerase inhibitor potentially for the treatment of HIV.

Chemical Structure

img
Lodenosine
CAS# 110143-10-7
Instruction

Theoretical Analysis

Hodoodo Cat#: H328052
Name: Lodenosine
CAS#: 110143-10-7
Chemical Formula: C10H12FN5O2
Exact Mass: 253.10
Molecular Weight: 253.237
Elemental Analysis: C, 47.43; H, 4.78; F, 7.50; N, 27.66; O, 12.64

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Lodenosine; 2'-F-dd-ara-A; 2'-Fluoro-2'; 3'-dideoxyarabinosyladenine; DDG-1; FddA; Fddl; NSC-613792.

IUPAC/Chemical Name: ((2S,4S,5R)-5-(6-amino-9H-purin-9-yl)-4-fluorotetrahydrofuran-2-yl)methanol

InChi Key: KBEMFSMODRNJHE-JFWOZONXSA-N

InChi Code: InChI=1S/C10H12FN5O2/c11-6-1-5(2-17)18-10(6)16-4-15-7-8(12)13-3-14-9(7)16/h3-6,10,17H,1-2H2,(H2,12,13,14)/t5-,6-,10+/m0/s1

SMILES Code: OC[C@H]1O[C@@H](N2C=NC3=C(N)N=CN=C23)[C@@H](F)C1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 253.24 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Bei N, Li G, Meng Z, Weng Y, Zavala M, Molina LT. Impacts of using an ensemble Kalman filter on air quality simulations along the California-Mexico border region during Cal-Mex 2010 field campaign. Sci Total Environ. 2014 Nov 15;499:141-53. doi: 10.1016/j.scitotenv.2014.07.121. PubMed PMID: 25181046.

2: Rahman Z, MacFalls H, Jiang K, Chan KF, Kelly K, Tournas J, Stumpp OF, Bedi V, Zachary C. Fractional deep dermal ablation induces tissue tightening. Lasers Surg Med. 2009 Feb;41(2):78-86. doi: 10.1002/lsm.20715. PubMed PMID: 19226572.

3: Katayama S, Takamatsu S, Hirose N, Izawa K, Maruyama T. Synthesis of fluorinated nucleosides. Curr Protoc Nucleic Acid Chem. 2006 Jul;Chapter 1:Unit 1.12. doi: 10.1002/0471142700.nc0112s25. PubMed PMID: 18428944.

4: Saravanan G, Ozeki S. Magnetic field control of electron tunneling pathways in the monolayer of (ferrocenylmethyl)dodecyldimethylammonium bromide on a gold electrode. J Phys Chem B. 2008 Jan 10;112(1):3-6. PubMed PMID: 18076154.

5: Izawa K, Takamatsu S, Katayama S, Hirose N, Kozai S, Maruyama T. An industrial process for synthesizing Lodenosine (FddA). Nucleosides Nucleotides Nucleic Acids. 2003 May-Aug;22(5-8):507-17. PubMed PMID: 14565226.

6: Maruyama T, Kozai S, Takamatsu S, Izawa K. Introduction of a benzoyl group onto 6-chloropurine riboside in aqueous solution and its application to the synthesis of nucleoside derivatives. Nucleic Acids Symp Ser. 2000;(44):103-4. PubMed PMID: 12903289.

7: Mendoza-Dominguez A, Russell AG. Emission strength validation using four-dimensional data assimilation: application to primary aerosol and precursors to ozone and secondary aerosol. J Air Waste Manag Assoc. 2001 Nov;51(11):1538-50. PubMed PMID: 11720101.

8: Takamatsu S, Maruyama T, Katayama S, Hirose N, Naito M, Izawa K. Synthesis of 9-(2,3-dideoxy-2-fluoro-beta-D-threo-pentofuranosyl)adenine (FddA) via a purine 3'-deoxynucleoside. J Org Chem. 2001 Nov 2;66(22):7469-77. PubMed PMID: 11681963.

9: Luy B, Barchi JJ Jr, Marino JP. S(3)E-E.COSY methods for the measurement of (19)F associated scalar and dipolar coupling constants. J Magn Reson. 2001 Sep;152(1):179-84. PubMed PMID: 11531377.

10: Antiretroviral update from the Interscience Conference on Antimicrobial Agents and Chemotherapy. Newsline People AIDS Coalit N Y. 1998 Dec:16-8. PubMed PMID: 11367083.

11: Death halts study. Posit Aware. 2000 Jan-Feb;11(1):23. PubMed PMID: 11366339.

12: Gallant JE. New antiretroviral agents. Hopkins HIV Rep. 1999 Mar;11(2):3, 12. PubMed PMID: 11366248.

13: Hanna L. FddA: antiretroviral in development. BETA. 1998 Oct:7-8. PubMed PMID: 11365997.

14: Srinivas NR, Shyu WC. Single dose and multiple dose pharmacokinetics of 2'-fluoro-2',3'-dideoxyadenosine and 2'-fluoro-2',3'-dideoxyinosine, anti-HIV agents, in rats. Eur J Drug Metab Pharmacokinet. 1999 Oct-Dec;24(4):329-34. PubMed PMID: 10892896.

15: Ueno T, Mitsuya H. Comparative enzymatic study of HIV-1 reverse transcriptase resistant to 2',3'-dideoxynucleotide analogs using the single-nucleotide incorporation assay. Biochemistry. 1997 Feb 4;36(5):1092-9. PubMed PMID: 9033399.

16: Ruxrungtham K, Boone E, Ford H Jr, Driscoll JS, Davey RT Jr, Lane HC. Potent activity of 2'-beta-fluoro-2',3'-dideoxyadenosine against human immunodeficiency virus type 1 infection in hu-PBL-SCID mice. Antimicrob Agents Chemother. 1996 Oct;40(10):2369-74. PubMed PMID: 8891146; PubMed Central PMCID: PMC163536.

17: Campbell DA, Shah VR, Srinivas NR, Shyu WC. High-performance liquid chromatographic analysis of 2'-fluoro-2',3'-dideoxyadenosine and 2'-fluoro-2',3'-dideoxyinosine in dog plasma and urine. J Pharm Sci. 1996 Aug;85(8):890-2. PubMed PMID: 8863284.

18: Benveniste P, Zhu W, Cohen A. Interference with thymocyte differentiation by an inhibitor of S-adenosylhomocysteine hydrolase. J Immunol. 1995 Jul 15;155(2):536-44. PubMed PMID: 7608534.

19: Comereski CR, Kelly WA, Davidson TJ, Warner WA, Hopper LD, Oleson FB. Acute cardiotoxicity of nucleoside analogs FddA and FddI in rats. Fundam Appl Toxicol. 1993 Apr;20(3):360-4. PubMed PMID: 8504910.